Recent clinical trials regarding the intravitreal injection of anti-VEGF agents (ranibizumab, bevacizumab, pegaptanib, and aflibercept) have shown excellent results in the treatment of angiogenic pathologies including choroidal neovascularization [1–10], macular edema [11–18], proliferative diabetic retinopathy [19–23], and neovascular glaucoma (NVG) [24–32]. The gene discussed is VEGFA; the disease is macular retinal edema.